Are you a medical innovator? Have you got a game-changing medical or surgical innovation to share with the world? We'd love to feature your work and ideas in our new Spotify podcast at Combat Innovators – The Present and Future of Cancer Treatment.
#HIVEC #HIPEC #CombatCancer
Great to hear an #ovariancancer success story. Sadly, only 33% are diagnosed at stage 1 (>5 year survival rate 90%). We're developing a normothermic intraperitoneal chemo treatment to improve outcomes for late-stage disease.
#medicalinnovation #worldcancerday #CombatCancer
Want to share this with all of you. It’s been quite the year, and I am feeling very grateful! 🙏❤️
https://www.espn.com/tennis/story/_/id/35461249/chris-evert-updates-cancer-journey-one-year-later
HIPECT4 – phase III, randomized, open-label controlled trial – adjuvant hyperthermic intraperitoneal chemotherapy in locally advanced colorectal cancer. result? Reduced risk of relapse, especially in patients with pT4 colorectal CA.
#medicalinnovation #HIPEC #CombatCancer
Thanks my friend, this is one additional action to do in our patients to complemente the good surgery https://twitter.com/gomezjorgemd/status/1617955271128813569
@LucyBowden20 @HillUrology @BladderCancerUK @CombatCancer Great work
First Hivec patient today @HillUrology Looking after our @BladderCancerUK patients. Thanks to @CombatCancer
51% of patients had a complete response. Of those who responded, 46% remained in complete response for at least 1 yr. Hmm. A complete response rate of 23% after 1 yr. Combat’s #HIVEC with MMC = 70% complete response after 1 yr (Stemberger et al, 2022). #CombatCancer
The FDA recently approved the first gene therapy for treating high-risk bladder cancer that doesn’t respond to immunotherapy with bacillus Calmette- Guérin, commonly used to treat adults with non-muscle-invasive bladder cancer. https://ja.ma/3Heu4DL #MedicalNews
Quick heads up – who’s going to #ArabHealth2023 in Dubai at the end of January?
#medicalinnovation #arabhealth #ah23 #bladdercancer #colorectalcancer #ovariancancer #pancreaticcancer #HIPEC #HIVEC #CombatMedical
“The study showed that surgery combined with HIPEC was more effective in terms of time to local recurrence for patients with pathomorphologically confirmed stage T4 (pT4) colorectal cancer.”
#medicalinnovation #colorectalcancer #HIPEC #CombatCancer
Since HIPECT4 trial has demonstrated reducing risk of peritoneal relapse in t4 colon cancer the debate is now open, great reflection published in @AnnSurgOncol @myESMO @PSOGI_EC @ESSOnews @GECOPeritoneal @operarelcancer @ISSPP1 @Annals_Oncology @HUReinaSofia @IMIBIC https://twitter.com/segurajuanj/status/1616107720528039937
Peritoneal metastasis in locally advanced #coloncancer has a poor prognosis in the 3 years post surgical resection. The HIPECT4 phase III trial is the first to show the benefits of mitomycin C administered with surgery via #HIPEC – @alarjosan 👏👏
#medicalinnovation #CombatCancer
After HIPECT4 results decreasing the risk of peritoneal relapse in cT4 colon cancer, we use this approach routinely, and you? Publication is coming ! https://touchoncology.com/gastrointestinal-oncology/conference-hub/alvaro-arjona-sanchez-esmo-2022-hipect4-phase-3-trial-investigating-the-efficacy-and-safety-of-adjuvant-hipec-in-patients-with-locally-advanced-colon-cancer/ @GECOPeritoneal @operarelcancer @myESMO @ESSOnews @_SEOM @aecirujanos @indepso @ISSPP1 @PSOGI_EC
Get your thumbs warmed up-@PSOGI_EC Case of the month numb 1 of this year is starting in 10 minutes! See you soon @almogby2 @AndreasBrandl8 @indepso @drarturreis @SPeritoneum @VadimGushchin6 @ESSOnews @DrFloresAyala
